Cytek Biosciences, Inc. (CTKB) AI Stock Analysis

Cytek Biosciences, Inc. provides tools and systems that enable comprehensive cell analysis for biomedical research and clinical applications. Its flagship products include the aurora and northern lights systems, which are advanced spectrum flow cytometers using multiple lasers to distinguish fluorescent tags on cells. The company also offers the aurora cell sorter system powered by full spectrum profiling technology. In addition to instruments, Cytek supplies reagents and kits, such as cFluor fluorochrome-conjugated antibodies, the 25-color immunoprofiling assay for human immune subpopulation identification, and automated micro-sampling and sample loading systems to optimize workflow efficiency.

Revenue increased from $128.0M in FY2021 to $201.5M in FY2025, reflecting a 5-year CAGR of 16.8% from FY2020 to FY2025, though annual revenue growth slowed to 0.5% in FY2025. Gross margin contracted from 61.9% in FY2021 to 51.8% in FY2025. Operating margin declined over the same period, reaching -20.0% in FY2025. Net income fell from $3.0M in FY2021 to -$66.5M in FY2025, generating an EPS of -$0.12. In the latest quarter ended June 30, 2026, quarterly revenue grew 5.6% year-over-year, while quarterly earnings grew 73.5%. Over the trailing twelve months, revenue was $206.7M with an operating margin of -29.5%.

As of June 30, 2026, Cytek Biosciences held $262.0M in cash and short-term investments against total debt of $26.5M, leaving a net cash balance of $235.5M. The company reported a current ratio of 4.48 and a debt-to-equity ratio of 0.08, with shareholders' equity of $322.0M. In FY2025, operating cash flow was -$4.7M and free cash flow was -$8.8M. Cash outlays in FY2025 included $4.1M in capital expenditures and $15.1M in share buybacks.

At a last close of $5.25 on October 16, 2026, Cytek Biosciences traded at an enterprise value of $502.8M and a forward P/E of 370.4x, well above the 17.3x forward P/E median of its US-listed Healthcare peers. Its EV/EBITDA stood at 222.7x compared to the peer median of 12.0x, while its price-to-sales ratio of 3.3x sat below the peer median of 4.1x. Over the past year, the stock returned 30.6%, outpacing the S&P 500 (SPY) return of 16.8%. However, its 5-year return of -78.2% trailed the S&P 500 return of 83.0%.

Wall Street coverage includes 1 Strong Buy, 1 Buy, and 2 Hold ratings. The mean price target of $5.56 represents an upside of 6.0% from the last close of $5.25. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $209.4M and an EPS of -$0.12. For next fiscal year, projected revenue is $223.2M with EPS of $0.07. The company has beaten EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 4, 2026.

This page is an AI-written research summary of Cytek Biosciences, Inc. (CTKB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CTKB income statement, CTKB balance sheet, CTKB key metrics, CTKB analyst forecast, CTKB chart. See the CTKB stock overview for the latest quote and news.